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Extracellular proteases of the matrix metalloproteinase (MMP) and serine protease families participate in many aspects of tumour
growth and metastasis. Using quantitative real-time RT–PCR analysis, we have undertaken a comprehensive survey of the expression
of these enzymes and of their natural inhibitors in 44 cases of human prostate cancer and 23 benign prostate specimens. We found
increased expression of MMP10, 15, 24, 25 and 26, urokinase plasminogen activator-receptor (uPAR) and plasminogen activator
inhibitor-1 (PAI1), and the newly characterised serine proteases hepsin and matriptase-1 (MTSP1) in malignant tissue compared to
benign prostate tissue. In contrast, there was significantly decreased expression of MMP2 and MMP23, maspin, and the protease
inhibitors tissue inhibitor of metalloproteinase 3 (TIMP3), TIMP4 and RECK (reversion-inducing cysteine-rich protein with Kazal motifs)
in the cancer specimens. The expression of MMP15 and MMP26 correlated positively with Gleason score, whereas TIMP3, TIMP4 and
RECK expression correlated negatively with Gleason score. The cellular localisation of the expression of the deregulated genes was
evaluated using primary malignant epithelial and stromal cell cultures derived from radical prostatectomy specimens. MMP10 and 25,
hepsin, MTSP1 and maspin showed predominantly epithelial expression, whereas TIMP 3 and 4, RECK, MMP2 and 23, uPAR and PAI1
were produced primarily by stromal cells. These data provide the first comprehensive and quantitative analysis of the expression and
localisation of MMPs and their inhibitors in human prostate cancer, leading to the identification of several genes involved in proteolysis
as potential prognostic indicators, in particular hepsin, MTSP1, MMP26, PAI1, uPAR, MMP15, TIMP3, TIMP4, maspin and RECK.
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Prostate cancer will affect one man in five and is now the leading
cause of cancer deaths in Western men (Levi et al, 2004). The
biological mechanisms underlying its initiation and progression
are incompletely understood and there is an urgent need for the
identification of robust prognostic markers, so that the most
effective treatment can be provided. For example, the optimum
treatment of patients with localised prostate cancer is uncertain
and the identification of molecular markers that are predictive of
increased malignant potential could make an important contribu-
tion to therapeutic decision-making.
Degradation of the extracellular matrix (ECM) is integral in
tumorigenesis and is mediated by the activity of ECM proteases,
including the matrix metalloproteinases (MMPs) and the serine
proteases (Sternlicht and Werb, 2001; Egeblad and Werb, 2002).
There are 24 members of the human MMP family (Lopez-Otin and
Overall, 2002) that have a number of other roles in tumorigenesis,
including a direct role in ECM degradation mediating tumour
establishment, growth and migration, avoidance of apoptosis,
angiogenesis and interaction with the immune system. These
effects are achieved in part by the cleavage of growth factors, their
receptors, or other growth factor-associated proteins (Egeblad and
Werb, 2002). Matrix metalloproteinase activity is regulated at
several levels. Activation of most MMPs occurs extracellularly and
is mediated by proenzyme cleavage involving other MMPs and
serine proteases, in particular the plasminogen activator-plasmi-
nogen network (Egeblad and Werb, 2002). An important means of
their inhibition is achieved by the binding of the tissue inhibitors
of metalloproteases (TIMPs), of which there are four members
(Jiang et al, 2002; Baker et al, 2002). In addition, the recently
characterised MMP inhibitor, RECK (reversion inducing cysteine-
rich protein with Kazal motifs) can exert effects on the synthesis,
activation and activity of several MMPs (Oh et al, 2001; Sasahara
et al, 2002). Members of the serine protease family have been
shown to be important in a variety of malignant tumours. In
particular, the plasminogen activator system, which mediates cell
surface plasmin generation via association of urokinase plasmino-
gen activator (uPA) with its glyco-phosphoinositol-anchored
receptor (uPAR), thus leading to degradation of pericellular
proteins directly, as well as indirectly through activation of several
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spro-MMPs (Andreasen et al, 2000; Egeblad and Werb, 2002; Ellis,
2003; Freije et al, 2003). Moreover, transmembrane serine
proteases (e.g. hepsin and matriptase) have also been implicated
in tumorigenesis, but their roles are as yet unresolved (Dhanase-
karan et al, 2001; Stamey et al, 2001; Srikantan et al, 2002; Chen
et al, 2003; Galkin et al, 2004).
There is considerable evidence supporting the involvement of
MMPs and TIMPs in prostate cancer (Pajouh et al, 1991;
Lokeshwar et al, 1993; Boag and Young, 1994; Wood et al, 1997;
Hashimoto et al, 1998; Still et al, 2000; Srikantan et al, 2002; Trudel
et al, 2003; Udayakumar et al, 2003; Zhao et al, 2003). However,
research has focused almost entirely on the earlier discovered
MMPs (MMP-2, -7 and -9) and TIMP-1 and -2; the more recently
discovered MMPs have received little attention (Zhao et al, 2003).
Similarly, little is known of the potential roles of the transmem-
brane serine proteases and their inhibitors. However, recent data
from microarray profiling studies have linked hepsin with prostate
cancer pathogenesis (Dhanasekaran et al, 2001; Stamey et al, 2001;
Ernst et al, 2002; Chen et al, 2003).
In this study we investigated the expression of the entire MMP
and TIMP families, RECK, and selected serine proteases and
inhibitors in a large collection of primary malignant and
nonmalignant prostate tissues. In the absence of monoclonal
antibodies of equivalent specificity and sensitivity, we used
quantitative real-time PCR assay (Nuttall et al, 2003) to measure
mRNA levels. In order to investigate the cellular localisation of
these genes, we measured mRNA levels in primary epithelial and
stromal cell cultures derived from malignant prostate tissues.
These data provide the first detailed descriptions of the stromal vs
epithelial origin of the expression of the proteases and inhibitors,
and indicate that several proteolysis-associated genes may be
useful prognostic indicators in prostate cancer.
MATERIALS AND METHODS
Clinical samples
Samples of malignant and nonmalignant human prostate tissue
were obtained from the Partners in Cancer Research Tissue Bank,
held in the Department of Histopathology at the Norfolk &
Norwich University Hospital (NNUH). Detailed procedures for
obtaining informed patient consent, tissue acquisition, and
histopathological and molecular quality control and validation
have already been described (Riddick et al, 2003). Samples of
malignant prostate tissue were collected from patients undergoing
radical prostatectomy or channel transurethral resection of the
prostate (TURP), and nonmalignant samples were obtained from
patients undergoing radical cystoprostatectomy for transitional
cell carcinoma of the bladder or TURP for benign prostatic
hyperplasia. Gene expression profiling was undertaken in malig-
nant tissue samples from 44 patients with adenocarcinoma of the
prostate (four with Gleason scores 5–6, 25 with Gleason score 7,
and 15 with Gleason scores 8–10) and in nonmalignant samples
from 23 other patients with benign prostatic hyperplasia. The data
were further analysed to relate gene expression to increasing
Gleason score.
Primary culture of malignant epithelial and stromal cells
from adult, human prostate
Malignant human prostate tissue was obtained, with patient
consent, from nine patients (age range 52–68 years) undergoing
radical prostatectomy for prostate cancer. One sample was derived
from a Gleason grade 6 carcinoma and the remaining specimens
from grade 7 tumours. The presence of prostate cancer was
confirmed by histological examination of representative fragments.
The tissue was prepared as described previously (Collins et al,
2001). Briefly, collagenase digestion released epithelial structures
(organoids; glands and ducts), which where subsequently sepa-
rated from the stromal fraction by repeated unit gravity
centrifugation. The stromal cells were routinely cultured in RPMI
1640 medium supplemented with 10% foetal calf serum (FCS) and
the antibiotics penicillin (100Uml
 1; Invitrogen) and streptomy-
cin (100mgml
 1; Invitrogen). Epithelial cultures were grown in
keratinocyte serum-free medium (KSFM; Invitrogen) with anti-
biotics as above. For RNA extraction, stromal and epithelial
primary cell cultures were grown until 70% confluent and were
lysed directly, without trypsinisation.
RNA extraction and reverse transcription
Total RNA from the prostate tissues was isolated by first
homogenising tissues in RNAzol (Biogenesis, Poole, UK) and then
by using the Promega SV Total RNA Isolation System (Promega
Corporation, USA) to remove DNA and purify the RNA. RNA was
resuspended in nuclease free water and concentrations determined
by spectrophotometry using a GeneQuant pro RNA/DNA calcu-
lator (Amersham Pharmacia Biotech, Buckinghamshire, UK). For
the primary cell cultures, total RNA was extracted using an RNeasy
mini kit (Qiagen). In total, 1mg of total RNA was reverse
transcribed using 2mg random hexamers (Amersham) and 200U
of Superscript II reverse transcriptase (Life Technologies, Paisley,
UK), according to the supplier’s instructions. cDNA was stored at
 201C until used in the PCR reaction.
Quantitative real-time PCR
For PCR reactions, specific primers and fluorogenic probes for all
known human MMP and TIMP genes, RECK, hepsin, matriptase-1
(MTSP1), matriptase-2 (MTSP2), maspin, urokinase-type plasmi-
nogen activator (uPA) urokinase-type plasminogen activator
receptor (uPAR), hepatocyte growth factor and activator (HGF
and HGFA), and plasminogen activator inhibitor types-1 and -2
(PAI1, PAI2) were designed using Primer Express 1.0 software (PE
Applied Biosystems) and synthesised by PE Applied Biosystems;
sequences for primers and probes for the serine proteases are
given in Table 1. Where possible, to prevent the amplification of
genomic DNA and to ensure that the PCR signal was generated
from cDNA, primers were generated with sequences within
different exons, close to intron–exon boundaries. BLASTN
searches (Altschul et al, 1990) were conducted on all primer/
probe nucleotide sequences to ensure gene specificity. The identity
of PCR products was confirmed by direct sequencing of the
amplicon. The 18S ribosomal RNA gene was used as an
endogenous control to normalise for differences in the amount
of total RNA in each sample, using previously validated procedures
(Wall and Edwards, 2002; Nuttall et al, 2003); 18S rRNA primers
and probe were purchased from PE Applied Biosystems. PCR
reactions were performed as described (Nuttall et al, 2003), with
each reaction containing 5ng of reverse transcribed RNA in 25ml.
To determine the relative RNA levels within the samples, standard
curves for the PCR reaction were prepared by using the cDNA
from one sample and making two-fold serial dilutions covering the
range equivalent to 20–0.625ng of RNA (for 18S analyses, the
range was 4–0.125ng).
Statistical analysis
The data did not satisfy normality or equal variance, so
nonparametric tests were used. The Mann–Whitney U test was
carried out to compare malignant and nonmalignant samples.
Further tests were carried out using the two-tailed Spearman rank
correlation coefficient to determine whether there were associa-
tions with the Gleason sum score. Finally, the epithelial and
stromal cell culture populations derived from malignant prostate
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ssamples were also compared using the nonparametric Mann–
Whitney U-test. For all tests, a P-value of less than 0.05 was
considered statistically significant.
RESULTS
Expression of proteases and inhibitors in surgical
specimens of prostate tissue
Our tissue banking technique and quality assurance procedures
have been described in detail (Riddick et al, 2003). Briefly, a 9-mm
Table 1 Primer-probe sequences of the genes analysed by quantitative RT–
PCR. Sequences for the primers and probes are shown in 50 to 30 orientation
Gene name Primer/probe sequence
Hepsin
Forward primer GAGGAGAACAGCAACGATATTGC
Reverse primer CCCGTCACGGTACAGATCTTG
Probe CTCACAGAATACATCCAGCCTGTGTGCCT
MTSP1
Forward primer CACCTCAGTGGTGGCTTTCC
Reverse primer GCGTGCAGGCCAAAGCT
Probe CAAAACAGTACAGAGGACCCAGGACAACAGC
MTSP2
Forward primer CAGAAGATGCTCAAGGAGCTCAT
Reverse primer GGAATAGACGGAGCTGGAGTTG
Probe ACCAGCACCCGCCTGGGAACTTACT
Maspin
Forward primer CAGATGGCCACTTTGAGAACATT
Reverse primer GGCAGCATTAACCACAAGGATT
Probe GGCAGCATTAACCACAAGGATT
UPA
Forward primer TGGAACTCTGCCACTGTCCTT
Reverse primer GGCCCACCTGCACATAGC
Probe ATAATTACTGCAGGAACCCAGACAACCGGA
UPAR
Forward primer GCCCAATCCTGGAGCTTGA
Reverse primer TTCCCCTTGCAGCTGTAACAC
Probe CTGCCGCAGAATGGCCGCC
PAI1
Forward primer CAGAGGTGGAGAGAGCCAGATT
Reverse primer CTGGTCCACGGCTCCTTTC
Probe GTGAAGACACACACAAAAGGTATGATCAGCAACTT
PAI2
Forward primer AGTGTCAATAAGCTGTTTGGTGAGA
Reverse primer TCTAGCTTCTTCTGCACATTCTAGGA
Probe CTTCCGGGAAGAATATATTCGACTCTGTCAGAAA
TPA
Forward primer AAACCCAGATCGAGACTCAAAGC
Reverse primer GGCTGACCCATTCCCAAAG
Probe CCTGCCTGCTCTGAGGGAAACAGTGAC
PSA
Forward primer TCTGCGGCGGTGTTCTG
Reverse primer CTGTGCCGACCCAGCAA
Probe CCACTGCATCAGGAACAAAAGCGTGAT
HGFA
Forward primer CATCGAGAAGTACATCCCGTACAC
Reverse primer CAGATGGGCTGCACGAACT
Probe CCAGCGACCACGACCTCGTCCT
HAI1
Forward primer CGCGGCATCTCCAAGAAG
Reverse primer AGCCTGTGCTGGGAATGG
Probe TGTGTTTGGCCTGAGGCGGGA
HAI2
Forward primer GCTCTGAGGAGGCCTGCAT
Reverse primer AAGAGGATCAACACCATCACGAA
Probe CTCCGCTGCTTCCGCCAGCA
Probes contain an FAM fluorescent reporter on the 50 end and a TAMRA quencher
on the 30 end. Primer-probe combinations for TIMP and RECK genes have been
described elsewhere (Nuttall et al, 2003). For the MMPs and TIMPs, primer and
probe sequences are the property of Applied Biosystems (Warrington, UK).
HGFA¼HGF activator.
Table 2 Summary of expression profiling of genes showing differential
expression between benign and malignant tissues, and relationships with
Gleason score
Gene
Malignant vs
non-malignant
Correlation with
Gleason score
Direction of
change in
malignancy
MMP1 P¼0.911 P¼0.533
MMP2 P¼0.004 P¼0.028/R¼ 0.286 k
MMP3 P¼0.835 ND
MMP7 P¼0.106 NS
MMP8 N/D ND
MMP9 P¼0.501 ND
MMP10 P¼0.016 P¼0.015/R¼ 0.297 m
MMP11 P¼0.539 ND
MMP12 P¼0.883 ND
MMP13 N/D ND
MMP14 NS NS
MMP15 Po0.0001 Po0.0001/R¼0.484 m
MMP16 NS NS
MMP17 NS NS
MMP19 P¼0.932 ND
MMP20 N/D ND
MMP21 P¼0.288 ND
MMP23 Po0.0001 Po0.0001/R¼ 0.497 k
MMP24 P¼0.014 P¼0.011/R¼0.289 m
MMP25 P¼0.003 NS m
MMP26 Po0.0001 Po0.0001/R¼0.507 m
MMP27 N/D ND
MMP28 P¼0.736 ND
TIMP1 P¼0.183 ND
TIMP2 P¼0.126 ND
TIMP3 P¼0.001 Po0.0001/R¼ 0.430 k
TIMP4 P¼0.004 Po0.0001/R¼ 0.411 k
RECK Po0.0001 Po0.0001/R¼ 0.423 k
Hepsin Po0.0001 Po0.0001/R¼0.677 m
MTSP1 Po0.0001 Po0.0001/R¼0.496 m
MTSP2 P¼0.052 NS
PSA P¼0.702 NS
HGFA P¼0.424 NS
TPA P¼0.054 NS
uPA P¼0.04 P¼0.706/R¼0.047 m
uPAR P¼0.42 P¼0.014/R¼0.290 m
PAI1 P¼0.001 P¼0.004/R¼0.35 m
PAI2 P¼0.032 P¼0.028/R¼ 0.253 k
Maspin Po0.001 Po0.0001/R¼ 0.455 k
HAI1 P¼0.076 NS
HAI2 P¼0.166 P¼0.015/R¼ 0.279 k
Arrows in the right-hand column illustrate direction of change in gene expression
with malignancy. N/D¼not detected, NS¼not significant, ND¼not done. The
values given are derived from TaqMan expression data after normalisation to
18SrRNA levels, and are probe and, therefore, gene-specific. Comparison of
expression between genes is therefore not possible. The statistical test used was the
Mann–Whittney U test to compare malignant and non-malignant samples and the
two-tailed Spearman rank correlation test. HGFA¼HGF activator. Genes showing
statistically significant differences are indicated in bold.
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sMMP2
MMP15
MMP26
MMP23
RECK
MMP10
NM GS 5−6 GS 7 GS 8−10 NM GS 5−6 GS 7 GS 8−10
NM GS 5−6 GS 7 GS 8−10
NM GS 5−6 GS 7 GS 8−10 NM GS 5−6 GS 7 GS 8−10
NM GS 5−6 GS 7 GS 8−10
MTSP1
PAI1
HEPSIN
NM GS 5−06 GS 7 GS 8−10
MASPIN
NM GS 5−6 GS 7 GS 8−10 NM GS 5−6 GS 7 GS 8−10
NM GS 5−6 GS 7 GS 8−10
TIMP3
NM GS 5−6 GS 7 GS 8−10 NM GS 5−6 GS 7 GS 8−10
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Figure 1 Quantitative RT–PCR analysis of selected genes showing differential expression in benign vs malignant prostate tissues. Prostate tissue
specimens were sorted by Gleason Score (GS), and grouped as those with scores of 5–6, 7 or 8–10. The values of gene output are after normalisation to
18SrRNA and are probe, and therefore gene specific, thus precluding comparison of expression between genes. For summary of statistics see Table 2.
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spunch was used to remove a cylindrical core of tissue from the
transversely sliced prostate gland. The core was divided into four
quadrants prior to banking by snap freezing in isopentane
supercooled in liquid nitrogen. The histopathology of tissue at
the circumference of the remaining prostate from which the punch
was removed was used to predict the histopathology of the banked
tissue as previously validated (Riddick et al, 2003). Our expression
profiling strategy has focussed on secreted proteases and their
inhibitors, including 28 genes that encompass the entire human
MMP and TIMP families, as well as the novel MMP inhibitor
RECK. In addition, we have assessed the expression of the
components of the plasminogen activation system and the novel
transmembrane serine proteases, hepsin, MTSP1 and MTSP2, the
inhibitors PAI1, PAI2 HAI1, HAI2 and the serpin-related protein,
maspin. The serine proteases, prostate-specific antigen (PSA),
HGFA and tPA were also included for the purpose of comparison.
The complete data set of the RNA expression levels of protease
and inhibitor genes in benign and malignant human prostate
tissues is shown in Table 2 and data for selected genes are shown in
Figure 1. An overall comparison of malignant prostate tissues with
nonmalignant tissue samples obtained from prostates with BPH
revealed that gene expression levels of several MMPs and serine
proteases were significantly higher in the malignant samples.
These proteases include MMP10, 15, 24, 25 and 26, hepsin, MTSP1,
uPAR and also the inhibitor PAI1. By contrast, the levels of
expression of MMP2 and MMP23 were significantly lower in the
malignant samples, as were the inhibitors TIMP3, TIMP4, RECK,
and the serpin-related gene maspin. No significant difference was
seen between malignant and BPH samples for the expression of the
remaining members of the MMP family.
The data were further analysed to correlate gene expression to
increasing Gleason score (Gleason and Mellinger, 1974). Using the
Spearman correlation coefficient, we identified statistically sig-
nificant positive correlations with Gleason score for MMP10, 15, 24
and 26, and hepsin, MTSP1, uPAR and PAI1 when comparing the
increasing grades to benign or BPH controls (Table 2). In contrast,
there were statistically significant negative correlations for MMP2,
MMP23, maspin, TIMP3, TIMP4 and RECK.
Comparison of gene expression between primary stromal
and epithelial cells cultured from malignant prostates
Components of protease networks are frequently produced as a
host stromal response to the presence of malignant tumour cells in
human neoplasms. Thus, in order to define the cellular origins of
the proteases identified from the comprehensive gene expression
profile from bulk prostate tissue specimens, we undertook analysis
of primary cultures of epithelial and stromal cells from radical
prostatectomy tissues. Gene expression profiling of the primary
malignant epithelial and stromal cell types showed the statistically
significant and predominantly epithelial expression of MMP10 and
25, hepsin, MTSP1 and maspin (Table 3; Figure 2). By contrast,
there was a significantly greater expression of TIMP3, TIMP4,
RECK, MMP2, and 23, uPAR and PAI1 in stromal cells compared to
their epithelial counterparts. There were no significant differences
in the levels of gene expression in the epithelial and stromal cells
for MMP15, 24 and 26.
DISCUSSION
This study is the first comprehensive analysis of the expression of
the entire MMP and TIMP families in a large series of human
prostate tissue samples, including both malignant (adenocarcino-
matous) and nonmalignant (hyperplastic) tissue. In addition, the
differential expression of members of the serine protease family
emphasises the importance of evaluating more broadly the
components of the ‘degradome’ – the repertoire of proteases,
their inhibitors and associated molecules that each tissue deploys
(Lopez-Otin and Overall, 2002). Our data identify several
degradome genes as being differentially expressed, suggesting
roles in prostate tumorigenesis or as markers of prognosis. The
observations on fresh-frozen tissue samples have been extended by
analysis of primary cell cultures of prostatic adenocarcinoma cells
and stromal cells from the same neoplasms.
Matrix metalloproteinases
Of the MMPs studied, the greatest increase (B30 fold) in
expression levels in malignant compared to nonmalignant prostate
tissues was found for MMP26. The expression of MMP26 was also
found to correlate strongly with Gleason score, indicating its
potential as a prognostic marker in prostate carcinoma. MMP26
has only recently been implicated in tumorigenesis compared to
some of the earlier discovered MMPs, and its expression has been
found to be elevated in various epithelial neoplasms (Marchenko
et al, 2001). Indeed, Zhao et al (2003) have demonstrated elevated
expression in prostate cancer by immunohistochemical analysis of
a limited number of human specimens. Their findings are
consistent with the data presented in this study. The same authors
also reveal a mechanism of action for MMP-26 by demonstrating
its ability to activate pro-MMP-9 in ARCaP cells. In other studies,
Zhao et al (2004) showed that MMP-26 is important in the
activation of MMP-9 in breast carcinomas, where its activity is
inhibited by TIMPs-2 and -4, suggesting that the interplay between
these factors may be a significant determinant of malignancy in
both breast and prostate neoplasia.
Two MMPs (MMP2 and MMP23) were downregulated in
prostate cancer. There is growing recognition that MMPs can
exert inhibitory effects on tumour growth, potentially through the
generation of angiogenesis inhibitors such as endostatin and
Table 3 Analysis of gene expression in primary epithelial and stromal
fibroblast cell cultures from prostate tumours
Gene Epithelial Stromal P-value
Gene expressed predominantly by malignant epithelial cell cultures
MMP 10 1 0.01 0.009
MT6MMP 1 0.09 0.009
Hepsin 1 0 0.04
MTSP1 1 0.01 0.008
Maspin 1 0 0.009
cMet 1 0.28 0.029
HAI1 1 0.05 0.029
HAI2 1 0.03 0.029
Gene expressed predominantly by stromal cell cultures
MMP2 1 6.49 0.009
MMP23 1 21.44 0.009
TIMP3 1 15.22 0.009
TIMP4 1 7.6 0.047
RECK 1 50 0.009
UPAR 1 5.28 0.016
PAI1 1 14.37 0.028
HGF 1 1425 0.029
Genes showing no significant difference in expression between cell cultures
MMP26 0.566 0.25 0.175
MMP15 1.071 0.702 0.602
MMP24 0.605 22.435 0.076
uPA 48.388 5.168 0.076
HGFA 11 1
The values given are derived from TaqMan expression data after normalisation to
18SrRNA levels, and are probe and, therefore, gene-specific. Comparison of
expression between genes is not possible. All epithelial values have an arbitrarily fixed
value of 1 and the stromal expression relative to this is shown. The statistical test
used was the Mann–Whittney U-test.
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stumstatin by cleavage of ECM components (Kalluri, 2003; Lafleur
et al, 2003). Also, the absence of an MMP can promote
tumorigenesis, as shown by the enhanced susceptibility to skin
carcinogenesis displayed by Mmp8-null mice (Balbin et al, 2003). It
is not clear at present whether MMP2 and 23 might fulfill such a
role in prostate tumorigenesis, though their downregulated
expression suggests this as a possibility that warrants further
study.
Our data for MMP2 are consistent with those of Lichtinghagen
et al (2002), who studied the expression of MMP2 in human
prostate tissues using quantitative RT–PCR, but differ from
observations of MMP-2 protein levels using immunohistochem-
istry, where levels were increased in prostate cancer tissues
(Brehmer et al, 2003), and from a study that identified an increase
in transcript level in the highest grades of cancer (Still et al, 2000).
Elevated plasma MMP-2 activity has also been suggested to be
prognostic for prostate cancer metastasis (Morgia et al, 2005),
indicating that there may be a discrepancy between MMP2
RNA and protein levels in prostate tumours. However, the
precise spatial expression of MMP2 and its activators and
potential substrates will determine its role in disease pathogenesis,
and are likely be of more significance than its global level of
expression.
To date, there are no data concerning expression of membrane-
bound MMP-23 at the protein level. Elevation of three membrane-
type-MMPs (MT-MMPs) was also demonstrated in this study,
namely MMP15, MMP24 and MMP25 (MT2-, MT5- and MT6-
MMPs). These MT-MMPs can post-translationally activate pro-
MMP-2 (Llano et al, 1999; Nie and Pei, 2003). They also display
intrinsic proteolytic activity towards ECM molecules, which is
independent of MMP-2 activation. These proteases could thus
participate directly in prostate tumour invasion, and in this regard
it is important to note that MMP25 (MT6-MMP) is primarily
expressed by the epithelial cancer cells rather than stromal cells.
This was also the case for MMP10, which likewise showed elevated
expression in prostate cancer epithelium. Of note, Ernst et al
(2002) found no difference in expression of MMP10 between total
biopsies of benign and malignant prostate tissue. However,
comparison of microdissected malignant epithelium with benign
epithelium revealed a marked elevation of MMP10 in the
malignant cell population. This may explain why we found a
modest increase in MMP10 in the malignant samples, but were
unable to determine which Gleason grade was responsible for the
increase. Other studies have observed MMP10 upregulation in
oesophageal carcinomas (Mathew et al, 2002), recurrent lung
carcinomas (Cho et al, 2004) and in gliomas (Thorns et al, 2003),
where they predict a more malignant phenotype. Similarly, Van
Themsche et al (2004) found that induction of MMP10 expression
in lymphoma cell lines promoted their malignant phenotype.
TIMPs
The tissue inhibitors of metalloproteinases, which act as key
regulators of the MMPs, have important roles in tumorigenesis.
The expression of TIMP3 and TIMP4 decreased progressively with
increasing Gleason score, supporting the classic notion that these
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Figure 2 Differential expression of proteases in epithelium or stroma in primary prostate cell cultures. The figure shows QRT–PCR analysis of levels of
expression of selected genes in epithelial (black columns) and stromal (white columns) primary cell cultures from human prostate tumours. Genes witha
primarily epithelial pattern include hepsin, maspin, MTSP1 (matriptase-1) and MMP10, whereas stromally expressed genes are MMP2, MMP23, TIMP3 and
PAI1. The values of gene output are after normalisation to 18SrRNA and are probe, and therefore gene specific, thus precluding comparison of expression
between genes. For summary of statistics see Table 3.
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sinhibitors may be protective in tumour progression. Therefore,
reduced levels of expression of TIMP3 in this study verifies the
findings of Stamey et al (2001), who identified reduced levels of
TIMP3 expression by microarray analysis (in prostate tumour
samples compared with benign prostatic hyperplasia) and those of
Yamanaka et al (2003) who found hypermethylation of the TIMP3
gene promoter (resulting in repressed expression). The mechan-
isms of action for the TIMPs vary between members, with some
displaying growth promoting and antiapoptotic effects in some
tumour contexts. In addition, there is evidence for effects that are
independent of MMP inhibition. TIMP-3, which emerges as one of
the most consistently tumour inhibitory TIMPs, can promote
apoptosis by its selective effects on A Disintegrin And Metallo-
proteinase (ADAM)-mediated shedding of death-domain contain-
ing receptors (Ahonen et al, 2003). Independent of its MMP
inhibitory activity, TIMP-3 suppresses angiogenesis by blocking
the interaction of VEGF with VEGFR-2 (Qi et al, 2003). On the
other hand, TIMP-4 can either promote (Jiang et al, 2001;
Tunuguntla et al, 2003) or inhibit tumour progression, depending
on the nature of the tumour and mode of delivery (Wang et al,
1997; Celiker et al, 2001; Groft et al, 2001; Zhao et al, 2004).
TIMP1 and TIMP2 expression on the other hand was not altered
in our study. There have been previous studies demonstrating both
elevated (Hashimoto et al, 1998) and reduced levels of expression
(Lokeshwar et al, 1993; Brehmer et al, 2003) of these genes using
semiquantitative methods of analysing gene expression. Clearly,
further studies are required, particularly in view of the emerging
theme of TIMP-1 supporting tumour progression in lymphomas
(Guedez et al, 1998; Kossakowska et al, 2000; Oelmann et al, 2002;
Kuittinen et al, 2003; Liu et al, 2003), colorectal carcinoma
(Holten-Andersen et al, 2005), carcinoma of the breast (Lee et al,
2003; Porter et al, 2004), and skin tumorigenesis (Rhee et al, 2004).
RECK, a novel metalloprotease inhibitor, is tentatively thought to
limit tumour progression by inhibition of MMPs-2, -9 and -14
(each of which affects angiogenesis). Downregulation of RECK was
seen with increasing Gleason score, similar to TIMP3 and TIMP4.
Notably, TIMP3, TIMP4 and RECK were all expressed predomi-
nantly by stromal cells. We considered whether the decreased
expression of these stromally expressed genes (and also MMPs-2
and -23) in cancers compared to benign tissues might reflect a
change in the proportion of epithelial to stromal cells due to
expansion of the malignant epithelial compartment. However,
other genes that show a stromal expression pattern did not show
the same reduction, for instance, PAI1 and uPAR are elevated (see
below) and HGF, also stromal in origin (data not shown) was
unaltered in overall expression between benign and malignant
tissues. Thus, we argue that the proportion of stromal cells in the
prostate tissue homogenates does not vary appreciably between
benign and malignant tissues, and therefore the reduced expres-
sion of TIMP3, TIMP4 and RECK is most likely a functional
consequence of tumour–stromal interactions.
Serine proteases and inhibitors
Serine proteases of the uPA/plasminogen/plasmin cascade have
been implicated in prostate cancer progression, where they may
act independently or may activate MMPs. Our data show elevated
transcript levels of PAI1 and uPAR in cancer compared to benign
tissues, with no significant changes in expression of uPA mRNA
levels. Interestingly soluble uPAR (suPAR) levels are elevated in
the serum of prostate cancer patients (Miyake et al, 1999; McCabe
et al, 2000). It is likely therefore that the increased uPAR mRNA
expression that we observe in prostate stromal cells at least
partially underpins these increases. As with the TIMPs, the role of
PAI1 in malignancy may be paradoxical, since in some models it
promotes tumour invasion and angiogenesis. Moreover, elevated
expression of PAI1 has also been seen in lung, breast and ovarian
carcinomas (Robert et al, 1999; Pedersen et al, 2000; Salden et al,
2000; Borgfeldt et al, 2001). PAI1 has effects both on cell adhesion
and plasmin activation (Czekay and Loskutoff, 2004), and thus
both the extent and location of its expression in relation to its
interaction partners will determine its net contribution to
malignancy. Ours are the first data to demonstrate elevated
expression of PAI1 in prostate cancer, and given current knowl-
edge of the biology of PAI1, it is likely that it is relevant for the
promotion of cell invasion or tumour vascularisation.
Our data identify the transmembrane serine proteases hepsin
and matriptase-1 (MTSP1) as potentially strong prognostic
markers of prostate cancer. The marked elevation of hepsin in
malignant prostate tissues and correlation with increasing Gleason
score were in agreement with other data from microarray analyses
and real-time PCR studies (Dhanasekaran et al, 2001; Stamey et al,
2001; Ernst et al, 2002; Chen et al, 2003; Riddick et al, 2003;
Stephan et al, 2004). The functional importance of hepsin has been
shown by its overexpression in a transgenic mouse model of
prostate tumorigenesis, which led to basement membrane
disorganisation and enhanced metastasis (Klezovitch et al, 2004).
Elevated expression of MTSP1 in prostate cancer tissues and
positive correlation with increasing Gleason score are also novel
findings. The cell culture data indicate that its expression is
predominantly epithelial in origin, which is in keeping with other
tumour systems such as lung mesotheliomas (Hoang et al, 2004),
ovarian (Oberst et al, 2002), breast (Lin et al, 1997; Takeuchi et al,
1999; Oberst et al, 2001) and in epithelial tissues in general (Oberst
et al, 2003). Recent data have indicated that matriptase may have a
role in the activation of hepatocyte growth factor (Lee et al, 2000)
and it will be of interest to determine whether this is integral to its
action in the prostate, where there is evidence for participation of
increased HGF-Met signalling in tumour progression (You et al,
2003; Hall et al, 2004). Met and matriptase are epithelial in
origin, whereas HGF is stromally derived, thus supporting the
importance of epithelial–stroma interaction in tumorigenesis
(Lee et al, 2000).
Maspin, which has been shown to have tumour-suppressive
effects, was found to be downregulated in prostate cancer tissues in
agreement with Chen et al (2003). Members of our group have
shown that maspin is not functional as a serine protease inhibitor
(Bass et al, 2002), which has now been confirmed at the structural
level (Al Ayyoubi et al, 2004), where it has been shown that the
reactive centre loop necessary for inhibitory function is main-
tained in a highly constrained, inactive conformation. Its tumour
suppressive effects are likely due to other mechanisms, including
promotion of cell adhesive mechanisms, as shown by Abraham
et al (2003) where TRAMP C2N cells stably transfected with
maspin exhibited a lower tumorigenicity demonstrated by a
reduced growth rate, decreased metastatic potential and increased
adhesiveness to fibronectin and laminin. In another model, Cher
et al (2003) found that maspin inhibits osteolysis, tumour growth
and angiogenesis.
CONCLUSION
Our comprehensive survey has identified components of the
degradome as potential markers of prostate carcinoma. These data
identify MMP2, MMP10, MMP15, MMP26, MMP23, TIMP3,
TIMP4, hepsin, MTSP1, PAI1, uPAR and maspin as genes that
require further study at the protein level and via immunohisto-
chemical analysis to elucidate their contributions to prostate
cancer progression. The metalloproteinase and serine proteinase
pathways are not independent of each other and, indeed, converge
at the pericellular environment to mediate the proteolysis, which
potentially facilitates invasion of the ECM and other structures by
cancer cells. This study points towards future research avenues to
elucidate these interactions and to establish their relevance in
human prostate cancer.
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